1B-LSD

Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

Experimental drugs have extremely limited human consumption data. There is not enough reliable information about this substance. This is most likely because the substance is is not very old. Information on these substances is limite and incomplete. Please be cautioned. Always practice harm reduction.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.

Description

1B-LSD

Also known as:

1B-LSD (1-butanoyl-lysergic acid diethylamide) is an LSD analogue which appears to be about as potent as 1P-LSD (slightly more potent than LSD) and has a slightly shorter duration than that of LSD, again thought to be about the same as 1P-LSD. Released in late 2018, and marketed agressively as a replacement for 1P-LSD. 1B-LSD does not yet have a clearly established safety profile,

Summary

1B-LSD is closely related to LSD and 1P-LSD and is reported to produce near-identical effects. Little is known about the pharmacology of 1B-LSD, but it likely produces its psychedelic effects by acting on serotonin receptors in the brain. The original synthesis date of 1B-LSD is unknown.

Unlike most research chemicals, 1B-LSD has no prior record in the scientific literature. The first reports of 1B-LSD use surfaced in 2018 following its appearance on the online research chemical market. User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD.

1B-LSD is theorized to act as a prodrug for LSD. The similarities in chemical structure between 1B-LSD and LSD predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration. Characteristics effects include geometric visual hallucinations, time distortion, enhanced introspection, and ego loss.

Its classical psychedelic effects and favorable tolerability has led it to become popular among novel psychoactive substance users who use it interchangeably with LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of 1B-LSD. It is presumed to have a similar toxicity and risk profile as LSD, although no evidence currently exists to support this.

It is highly advised to use harm reduction practices if using this substance.

History

A lucid argument can then be made that lysergic acid N,N-dimethylamide is derived from lysergic acid amide rather than LSD. Carrying this theme to the next logical step one would then assume that the 1-alkyl and 1-acyl derivatives of the N,N-dimethyl isomer would also not be controlled by the CsA amendment.— Donald A. Cooper, Future Synthetic Drugs of Abuse, 1988.

Chemistry

It is similar to LSD and is named for the butyryl group bound to the nitrogen of the polycyclic indole group of LSD. The tetracyclic ergoline is characteristic of the chemical structure of ergot alkaloids.

In contrast to LSD, 1B-LSD has an additional N1-butyryl group.

Chemical modifications in the N1 position are among the most frequently performed changes in the ergoline system, as the Indole nitrogen is easily accessible for alkylations, acylations, Mannich reactions and Michael additions.

Subscribe for the latest updates

Dosing Guide

Oral
Light25-50ug
Common50-125ug
Strong125-250ug

Duration

1B-LSD Duration Data
Onset45-90 minutes
Duration8-12 hours
After-effects6-24 hours

Interactions and Synergies

There are no existing interaction or synergy data for this drug.

General Information

Experiences
Oral
Vaporization
Come up
Dosage
Effects
After Effects
Avoid
Warning
Risks
Test Kits
Marguis Test Result
Tolerance
Detection
Half-life
Advice
Note
Note 2:
Note 3:

Effects

Pharmacological Effects

Based on its structural similarity to LSD, 1B-LSD likely acts as a partial agonist at the 5-HT2A receptor. The psychedelic effects are thought to primarily come from its efficacy at the 5-HT2A receptors distributed throughout the brain. 1B-LSD also likely displays binding activity at a wide range of monoamine receptors, such as those for dopamine and norepinephrine. However, there is currently no data to support these claims. It has been theorized that 1B-LSD (as well as the acyl homologs 1P-LSD and ALD-52) is deacylated in the body to LSD by elimination of butyric acid, as shown by studies with human blood serum.

Subjective Effects

Anecdotal reports from many users suggest that the subjective effects of 1B-LSD are so similar to that of LSD so as to be virtually indistinguishable from one another. In comparison to other psychedelics such as psilocybin, LSA and ayahuasca, 1B-LSD is significantly more stimulating and fast-paced regarding the specific style of its physical and cognitive effects.

Physical Effects

  • Stimulation - 1B-LSD is usually regarded as very energetic and stimulating without being forced. For example, when taken in any environment it will usually encourage physical activities such as running, walking, climbing or dancing. In comparison, other more commonly used psychedelics such as psilocybin which are generally sedating and relaxed.
  • Spontaneous bodily sensations - The "body high" of 1B-LSD can be characterized as proportionally very intense in comparison to its accompanying visual and cognitive effects. It behaves as a euphoric, fast-moving, sharp and location-specific tingling sensation. For some, it is manifested spontaneously at different, unpredictable points throughout the trip, but for most, it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. At moderate to high doses of 1B-LSD, this sensation often approaches its highest level and can become so overwhelming that people may find themselves debilitated with pleasurable sensations.
    • Physical euphoria - It should be noted that this effect is not as reliably induceable as it is with substances like stimulants or entactogens, and can just as easily manifest as extreme physical discomfort without any apparent reason.
  • Tactile enhancement - Feelings of enhanced tactile sensations are consistently present at moderate levels throughout most 1B-LSD experiences. If level 8A geometry is reached, an intense sensation of suddenly becoming aware of and being able to feel every single nerve ending across a person's entire body all at once is consistently present.
  • Stamina enhancement - This is generally mild in comparison to the stamina enhancement produced by traditional stimulants.
  • Appetite suppression
  • Bodily control enhancement
  • Difficulty urinating
  • Excessive yawning - This effect is significantly less pronounced than it is with psilocybin and its related compounds, the four-position substituted tryptamines.
  • Nausea - Mild nausea is occasionally reported when consumed in moderate to high dosages and either passes instantly soon after the user has vomited or gradually fades by itself as the peak sets in.
  • Increased blood pressure
  • Increased heart rate
  • Increased perspiration
  • Muscle contractions
  • Muscle spasms
  • Pupil dilation
  • Increased salivation
  • Vasoconstriction - Vasoconstriction may lead to users feeling cold, especially in the extremities.
  • Seizure - The likelihood is largely extrapolated from the seizures that have been reported from the use of LSD. It is thought to mainly be a risk in those who are genetically predisposed to them, particularly while accompanied by physically taxing conditions such as states of dehydration, fatigue, undernourishment or overheating.

Psychological Effects

Visual Effects

Enhancements

Distortions

Geometry

The visual geometry of 1B-LSD can be described as more similar in appearance to that of 2C-B or 2C-I than psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful in scheme, synthetic in feel, multicoloured in scheme, flat in shading, sharp in edges, large in size, fast in speed, smooth in motion, angular in its corners, non-immersive in-depth and consistent in intensity.

In the case of higher-level geometry, this substance is level 8A dominant but is also capable of inducing 8B Geometry under the right circumstances.

Hallucinatory states

1B-LSD is capable of producing a full range of hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics, specifically tryptamines like DMT or psilocybin mushrooms. These effects include:

Auditory Effects

Sensory Effects

  • Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.

Transpersonal Effects

Legal Status

Internationally, 1B-LSD is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area in many countries, meaning that while it is not specifically illegal, individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.

  • Austria: 1B-LSD is technically not illegal but it may fall under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD, thus making it illegal to supply for human consumption.
  • Germany: 1B-LSD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
  • Latvia: 1B-LSD is illegal in Latvia. Although it is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
  • Lithuania: 1B-LSD is illegal in Lithuania and is specifically named on the list of illegal substances since June 5, 2019.
  • Sweden: Following its sale as a designer drug, 1B-LSD was made illegal in Sweden on January 26, 2016.
  • Switzerland: Legal status is uncertain and there is a significant chance it will be explicitly declared illegal on May 1, 2019 by Ordinance of the DFI on the lists of narcotic drugs, psychotropic substances, precursors and chemical adjuvants.
  • United Kingdom: 1B-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.
  • United States: Since 1B-LSD can be considered a prodrug for LSD, its possession and sale may be prosecutable in the United States under the Federal Analogue Act.

  • References

    1. Brandt, S. D.; Kavanagh, P. V.; Westphal, F.; Stratford, A.; Elliott, S. P.; Hoang, K.; Wallach, J.; Halberstadt, A. L. (2015). "Return of the lysergamides. Part I: Analytical and behavioural characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD)". Drug Testing and Analysis. 8 (9): 891–902. :10.1002/dta.1884.  1942-7603.
    2. "1B-LSD (Google Trends)". Retrieved January 1, 2020.
    3. Cooper, Donald A. (1988). "Future Synthetic Drugs of Abuse". Proceedings of the international symposium on the forensic aspects of controlled substances. p. 79.  978-0-93211-509-6.
    4. Wagmann, L.; Richter, L. H. J.; Kehl, T.; Wack, F.; Pettersson Bergstrand, M.; Brandt, S. D.; Stratford, A.; Maurer, H. H.; Meyer, M. R. (2019). "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures". Analytical and Bioanalytical Chemistry. 411 (19): 4751–4763. :10.1007/s00216-018-1558-9.  1618-2642.
    5. Armstrong, B. D.; Paik, E.; Chhith, S.; Lelievre, V.; Waschek, J. A.; Howard, S. G. (2004). "Potentiation of (DL)‐3,4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptior partial agonist d‐lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939". Neuroscience Research Communications. 35 (2): 83–95. :10.1002/nrc.20023.  1520-6769.
    6. Gudelsky, Gary A.; Yamamoto, Bryan; Nash, J. Frank (1994). "Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists". European Journal of Pharmacology. 264 (3): 325–330. :10.1016/0014-2999(94)90669-6.  0014-2999.
    7. Capela, J. P.; Fernandes, E.; Remião, F.; Bastos, M. L.; Meisel, A.; Carvalho, F. (2007). "Ecstasy induces apoptosis via 5-HT2A-receptor stimulation in cortical neurons". Neurotoxicology. 28 (4): 868–875. :10.1016/j.neuro.2007.04.005.  0161-813X. PMID 17572501.
    8. Nichols, David E. (2004). "Hallucinogens". Pharmacology & Therapeutics. 101 (2): 131–181. :10.1016/j.pharmthera.2003.11.002.  0163-7258.
    9. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089.  1556-9039.
    10. "Synthetische Drogen: Neues Gesetz soll "Legal Highs" bekämpfen" [Synthetic drugs: New law is to combat legal highs] (in German). Der Standard. September 28, 2011. Retrieved January 1, 2020.
    11. "Entwurf: Bundesgesetz, mit dem ein Bundesgesetz über den Schutz vor Gesundheitsgefahren im Zusammenhang mit Neuen Psychoaktiven Substanzen (Neue-Psychoaktive-Substanzen-Gesetz, NPSG) erlassen und das Suchtmittelgesetz (SMG) geändert wird" (PDF) (in German). Retrieved January 1, 2020.
    12. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
    13. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
    14. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
    15. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
    16. "LR SAM Įsakymas Dėl Narkotinių ir psichotropinių medžiagų sąrašų patvirtinimo" (in Lithuanian). Retrieved January 1, 2020.
    17. "31 nya substanser klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten [Public Health Agency of Sweden]. January 26, 2016. Retrieved January 1, 2020.
    18. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
    19. "Psychoactive Substances Act 2016". UK Government. Retrieved January 1, 2020.

    Resources

    Sources

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.